FNCRX
Price
$44.86
Change
+$0.79 (+1.79%)
Updated
Jun 2 closing price
Net Assets
532.53M
PGNAX
Price
$87.92
Change
+$1.77 (+2.05%)
Updated
Jun 2 closing price
Net Assets
1.02B
Interact to see
Advertisement

FNCRX vs PGNAX

Header iconFNCRX vs PGNAX Comparison
Open Charts FNCRX vs PGNAXBanner chart's image
FNCRX vs PGNAX Comparison Chart in %
View a ticker or compare two or three
VS
FNCRX vs. PGNAX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FNCRX is a Hold and PGNAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
PGNAX has more cash in the bank: 1.02B vs. FNCRX (533M). FNCRX pays higher dividends than PGNAX: FNCRX (0.86) vs PGNAX (0.79). FNCRX was incepted earlier than PGNAX: FNCRX (21 years) vs PGNAX (36 years). FNCRX (1.76) is less costly to investors than PGNAX (1.26). PGNAX is a more actively managed with annual turnover of: 57.00 vs. FNCRX (19.72). FNCRX (1000) and PGNAX (1000) have matching initial minimum investment requirements. PGNAX annual gain was more profitable for investors over the last year : 61.83 vs. FNCRX (54.55). FNCRX (110.95) and PGNAX (107.64) have equivalent 5 years return.
FNCRXPGNAXFNCRX / PGNAX
Total Expense Ratio1.751.26139%
Annual Report Gross Expense Ratio1.761.26140%
Fund Existence21 years36 years-
Gain YTD23.44525.96090%
Front LoadN/A6%-
Min. Initial Investment10001000100%
Min. Initial Investment IRAN/AN/A-
Net Assets533M1.02B52%
Annual Yield % from dividends0.860.79110%
Returns for 1 year54.5561.8388%
Returns for 3 years72.9884.2687%
Returns for 5 years110.95107.64103%
Returns for 10 years98.85191.2052%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REAL9.790.09
+0.93%
RealReal (The)
NGG80.640.64
+0.80%
National Grid PLC
FOSL4.13N/A
N/A
Fossil Group
GTLB31.82-1.97
-5.83%
GitLab
KTTA0.64-0.07
-9.79%
Pasithea Therapeutics Corp